World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
60
Citations
13100
World Ranking
3122
National Ranking
1236

Jacques H. Grosset publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Jacques H. Grosset sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 159 publications — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Jacques H. Grosset D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Jacques H. Grosset sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 60 D-Index — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Antibiotics
  • Tuberculosis

His scientific interests lie mostly in Tuberculosis, Mycobacterium tuberculosis, Isoniazid, Pharmacology and Pyrazinamide. His Tuberculosis study integrates concerns from other disciplines, such as Regimen, Internal medicine, Single-strand conformation polymorphism and Immunology. Jacques H. Grosset interconnects In vitro, Antibiotics, Microbiology, Virology and Virulence in the investigation of issues within Mycobacterium tuberculosis.

His Isoniazid study combines topics from a wide range of disciplines, such as Gastroenterology and Multiple drug resistance. His Pharmacology research integrates issues from Rifapentine, Pharmacotherapy and Rifamycin. The study incorporates disciplines such as Moxifloxacin, Chemotherapy and SQ109 in addition to Pyrazinamide.

His most cited work include:

  • Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis (485 citations)
  • Fluoroquinolones, tuberculosis, and resistance (321 citations)
  • A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis (314 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Tuberculosis, Pharmacology, Mycobacterium tuberculosis, Microbiology and Antibacterial agent. His studies deal with areas such as Regimen, Internal medicine, Immunology and Clofazimine as well as Tuberculosis. His research in Pharmacology intersects with topics in Moxifloxacin and Rifapentine.

His Mycobacterium tuberculosis research incorporates themes from In vitro, Mutant, Gene, Lung and Granuloma. The Microbiology study combines topics in areas such as Guinea pig, Virology, In vivo and Ratón. His Antibacterial agent research includes themes of Clarithromycin and Rifampicin.

He most often published in these fields:

  • Tuberculosis (50.33%)
  • Pharmacology (36.42%)
  • Mycobacterium tuberculosis (30.46%)

What were the highlights of his more recent work (between 2011-2019)?

  • Tuberculosis (50.33%)
  • Pharmacology (36.42%)
  • Clofazimine (15.23%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Tuberculosis, Pharmacology, Clofazimine, Rifapentine and Regimen. Jacques H. Grosset is interested in Mycobacterium tuberculosis, which is a field of Tuberculosis. His Pharmacology research is multidisciplinary, incorporating perspectives in Pyrazinamide, Ethambutol, Isoniazid and Bedaquiline.

His Ethambutol research includes elements of Culture conversion, Moxifloxacin and Clarithromycin. As a part of the same scientific family, Jacques H. Grosset mostly works in the field of Clofazimine, focusing on Dosing and, on occasion, Combination therapy and Guinea pig. His Rifapentine study incorporates themes from Rifamycin and TB chemotherapy.

Between 2011 and 2019, his most popular works were:

  • Targeting DnaN for tuberculosis therapy using novel griselimycins (168 citations)
  • Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis (104 citations)
  • New drugs for the treatment of tuberculosis: hope and reality. (96 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Bacteria
  • Antibiotics

His primary areas of investigation include Tuberculosis, Pharmacology, Clofazimine, Ethambutol and Mycobacterium tuberculosis. His research integrates issues of Gastroenterology and Regimen in his study of Tuberculosis. Regimen is closely attributed to Pyrazinamide in his study.

His Mycobacterium tuberculosis study combines topics in areas such as Complementation, Mutant, Efflux and Mutation. His work focuses on many connections between Culture conversion and other disciplines, such as Moxifloxacin, that overlap with his field of interest in Surgery. The various areas that Jacques H. Grosset examines in his Rifapentine study include Rifamycin and SQ109.

Best Publications

  • Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

    Vadim Makarov;Giulia Manina;Katarina Mikusova;Ute Möllmann

  • Fluoroquinolones, tuberculosis, and resistance

    Amy Sarah Ginsburg;Jacques H Grosset;William R Bishai

  • Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects.

    J J Rouby;E Martin De Lassale;P Poete;M H Nicolas

  • A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis

    Gyanu Lamichhane;Matteo Zignol;Natalie J. Blades;Deborah E. Geiman

  • Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: A molecular study

    B. Heym;N. Honoré;C. Schurra;S.T. Cole

  • Targeting DnaN for tuberculosis therapy using novel griselimycins

    Angela Kling;Peer Lukat;Deepak V. Almeida;Armin Bauer

  • Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans

    S. Etuaful;B. Carbonnelle;J. Grosset;S. Lucas

  • Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal

    Keira A. Cohen;Thomas Abeel;Abigail Manson McGuire;Christopher A. Desjardins

  • Dormancy Phenotype Displayed by Extracellular Mycobacterium tuberculosis within Artificial Granulomas in Mice

    Petros C. Karakousis;Tetsuyuki Yoshimatsu;Gyanu Lamichhane;Samuel C. Woolwine

  • Mycobacterium tuberculosis in the Extracellular Compartment: an Underestimated Adversary

    Jacques Grosset

  • Bactericidal Activity of the Nitroimidazopyran PA-824 in a Murine Model of Tuberculosis

    Sandeep Tyagi;E. Nuermberger;T. Yoshimatsu;K. Williams

  • Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease)

    Annick Chauty;Marie Françoise Ardant;Ambroise Adeye;Hélène Euverte

  • Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis

    Eric L. Nuermberger;Tetsuyuki Yoshimatsu;Sandeep Tyagi;Kathy Williams

  • In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis

    Baohong Ji;Nacer Lounis;Caroline Maslo;Chantal Truffot-Pernot

  • Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model

    K. N. Williams;C. K. Stover;T. Zhu;R. Tasneen

  • Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis

    Eric Nuermberger;Sandeep Tyagi;Rokeya Tasneen;Kathy N. Williams

  • Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis

    Deepak Almeida;Thomas Ioerger;Sandeep Tyagi;Si Yang Li

  • Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.

    J Grosset;C Truffot-Pernot;C Lacroix;B Ji

  • Role of the dosR-dosS Two-Component Regulatory System in Mycobacterium tuberculosis Virulence in Three Animal Models†

    Paul J. Converse;Petros C. Karakousis;Lee G. Klinkenberg;Anup K. Kesavan

  • Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance

    Christopher A. Desjardins;Keira A. Cohen;Keira A. Cohen;Vanisha. Munsamy;Thomas. Abeel;Thomas. Abeel

  • Iron and Mycobacterium tuberculosis infection

    Nacer Lounis;Chantal Truffot-Pernot;Jacques Grosset;Victor R. Gordeuk

  • Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis

    Ian M. Rosenthal;Rokeya Tasneen;Charles A. Peloquin;Ming Zhang

Frequent Co-Authors

Eric L. Nuermberger
Eric L. Nuermberger Johns Hopkins University
Petros C. Karakousis
Petros C. Karakousis Johns Hopkins University
William R. Bishai
William R. Bishai Johns Hopkins University
Vincent Jarlier
Vincent Jarlier Sorbonne University
Stewart T. Cole
Stewart T. Cole Institut Pasteur
Richard E. Chaisson
Richard E. Chaisson Johns Hopkins University
Mario Raviglione
Mario Raviglione University of Milan
David N. McMurray
David N. McMurray Texas A&M University
Emmanuelle Cambau
Emmanuelle Cambau Université Paris Cité
John W. Adamson
John W. Adamson University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Microbiology can open multiple career doors, but it’s also valuable to consider related online degrees that complement or offer alternative paths. For example, a child life specialist salary with bachelor degree highlights how a foundation in biological sciences can support roles in healthcare and patient support services.

For those with unique challenges, such as a criminal record, pursuing the best degree for felons offers a way to build a stable career. This includes fields closely linked to health sciences and administration that may align well with a background in microbiology or life sciences.

Healthcare roles are expanding, and specialized programs like functional medicine nurse practitioner programs provide an alternative clinical pathway for those interested in holistic and integrative approaches to patient care, drawing on microbiological knowledge.

Additionally, careers in health information, such as those achievable through certification in medical coding, offer strong earning potential. Understanding the certified professional coder salary can help students weigh options beyond traditional laboratory roles while staying within the healthcare ecosystem.

Best Scientists Citing Jacques H. Grosset

Trending Scientists

Recently Published Articles